Should Publishers Worry About Facebook's New News Feed?
Facebook’s Lindsey Shepard stands by the company’s latest news feed update, despite reports that users are sharing less about themselves on the platform.
“We actually send out thousands of surveys, really every single week, to hear from our community about things that are working for them, things that they love, and also things that honestly, we can be doing better,” the company’s Director of Product Marketing for News Feed, told Cheddar.
“What we’ve heard from people is that when they’re interacting with friends and family, when they’re having those thoughtful discussions and conversations, that feels like time well spent,” Shepard said.
The changes announced last week de-prioritize posts from publishers and brands in an effort to increase user engagement. While Facebook argues only pages with low engagement will be impacted, some outlets fear alienation, with the company even admitting users will spend less time on the platform.
The move may seem ironic given Facebook's recent push to get publishers to invest more heavily on content. But Shepherd isn't worried.
“What’s good for people, and what makes people really enjoy their Facebook experience, is really good for anyone that’s leveraging Facebook for their business."
For full interview [click here](https://cheddar.com/videos/facebooks-lindsey-shepard-talks-the-news-feed-reboot).
On Monday, football fans were stunned when Buffalo Bills safety Damar Hamlin collapsed and suffered cardiac arrest. Cheddar News explains the condition and the steps to take if you witness an incident.
What's being called an unprecedented breakthrough in cancer treatment recently completed a small trial at New York City's Memorial Sloan Kettering in 14 rectal cancer patients. The experimental trial with the drug dostarlimab resulted in 100 percent remission in all candidates, precluding the need for chemotherapy or surgery. Cheddar News anchor Hena Doba dives into this hopeful story.
Join Cheddar News as we break down the top headlines this morning including updates on the Jan. 6 hears, the PGA suspension of 17 of the world's best golfers, and NASA's plans to study UFOs.
Rick Pauls, President & CEO OF DiaMedica Therapeutics, joins Cheddar Innovates to discuss a new ischemic stroke treatment option that expands the window for effective therapy for stroke patients.
John Bencich, CEO of Achieve Life Sciences, joins Cheddar Innovates to discuss a new plant-based compound that's being used to fight nicotine addiction.
On this episode of Cheddar Innovates: CEO of Achieve Life Sciences discusses a new plant-based compound that's being used to fight nicotine addiction; President & CEO OF DiaMedica Therapeutics explains a new ischemic stroke treatment option that expands the window for effective therapy for stroke patients; Cheddar gets a look at Curiosity Stream's 'Asteroid Rush.'